Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours

Inclusion Criteria: * Histologically proven non-seminomatous germ cell tumour of combined GCT (NSGCT + seminoma)of the testis * Histologically proven vascular invasion of the primary tumour into the testicular veins or lymphatics * Clinical stage 1 patients (normal AFP and HCG, or optimum marker decline approaching normal levels after orchidectomy AND no evidence of metastases on CT of chest, abdomen and pelvis) * Men aged 16 years or over * Creatinine clearance \> 50 ml/min * No previous chemotherapy * WBC \> 1.5 x 10\^9/l and platelets 100 x 10\^9/l * Fit to receive chemotherapy * Able to start BEP(500) chemotherapy as part of 111 study within 6\* weeks of orchidectomy * Written informed consent \*If there are unavoidable delays this timescale can be extended to 8 weeks Exclusion Criteria: * All patients with pure seminoma * All patients with non-seminoma or combined NSGCT + seminoma \> stage 1 * All patients with no vascular invasion * Previous chemotherapy * Patients with second malignancy except contralateral TIN and contralateral germ cell tumour treated by orchidectomy and subsequent surveillance of more than 3 years * Co-morbidity precluding the safe administration of BEP(500) chemotherapy * Patients with renal function impairment (bilirubin \>1.25 x ULN and/or AST \>2 x ULN) * Patients with pre-existing neuropathy * Patients with pulmonary fibrosis * Patients with serious illness or medical conditions incompatible with the protocol